Mylan N.V. has acquired the global rights to Cold-EEZE, a cold remedy line of products, from ProPhase Labs Inc. Read More »

Mylan N.V. recently released a brief statement regarding the status of its Abbreviated New Drug Application for its generic iteration of GlaxoSmithKline's Advair Diskus bronchodilator product. Read More »

Shire PLC's recombinant ADAMTS13 drug, SHP655, has been given fast-track designation by the U.S. Food and Drug Administration. Read More »

Mylan N.V., a global pharmaceutical company, recently announced the U.S. Food and Drug Administration (FDA) tentatively approved the company's New Drug Application for Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate Tablets, 400 mg/300 mg/300 mg ("TLE400"). Read More »

Teva Pharmaceuticals Industries Ltd. has launched its authorized generic of Minastrin 24 Fe (norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets) 1 mg/20 mcg in the U.S. Read More »

Mylan N.V. recently announced that it settled a case relating to patents for Herceptin, from Genentech Inc. and F. Hoffman-La Roche Ltd., giving Mylan global licenses for its trastuzumab product. Read More »

The U.S. Food and Drug Administration recently issued its final approval for Mylan’s Abbreviated New Drug Application for its Exemestane Tablets in a 25mg dosage, which are a generic version of Pfizer’s Aromasin tablets. Read More »

Two U.S. Food and Drug Administration committees recently voted 18 to 8, with one abstention, that Endo International’s OPANA ER (oxymorphone hydrochloride extended release) no longer has a positive risk-to- benefits ratio. Read More »

Mylan N.V. recently launched its Desvenlafaxine extended-release tablets, a generic version of Pfizer’s Pristiq tablets, to treat major depressive disorder in the U.S. market in 50 and 100 mg doses. Read More »

Teva Pharmaceutical Industries Ltd. has launched generic Pristiq 1 (desvenlafaxine) extended-release tablets in 25, 50 and 100 mg in the United States.  Read More »

U.S. Congressmen Doug Collins (R-GA) and Dave Loebsack (D-IA) last week introduced a bill -- H.R. 1316, the Prescription Drug Price Transparency Act -- that they say would "require greater transparency from pharmacy benefit managers (PBMs)." In introducing the bill, the congressmen, along with Rep. Buddy Carter (R-GA) and others, took to the House floor to deliver what Drug Channels' Dr. Adam Fein referred to as a "60-minute rant" against PBMs. Read More »

The FDA has approved the New Drug Application from Teva Pharmaceutical Industries Ltd. and granted Priority Review for SD-809, a treatment for tardive dyskinesia.  Read More »

The recent 2017 Economic Report on Pharmacies and Pharmacy Benefit Managers by Drug Channels named the top 15 U.S. Pharmacies of 2016.  Read More »

The U.S. Federal Trade Commission has filed a civil action suit against a subsidiary of Shire, PLC, as part of a citizen petition submission regarding antibiotic Vancocin. Read More »

GSK Consumer Healthcare has launched Flonase Allergy Relief for the treatment of seasonal allergies. Read More »

Global pharmaceutical maker Mylan will host Investor Day on March 1 in New York City. Read More »

CBI's Formulary, Co-Pay and Access Summit will convene April 11-12 to address patient affordability barriers and more.  Read More »

GlaxoSmithKline was awarded damages, fees and interest on Jan. 31 as arbitration concluded with Pernix Therapeutics Holdings Inc.  Read More »

DePuy Synthes and Pacira Pharmaceuticals have entered into a partnership to promote pain reliever Exparel. Read More »

The U.S. Food and Drug Administration has given approval for the use of Narcan, an emergency treatment medication to counteract heroin overdoses, in a nasal spray form. Read More »